ArticleProstate cancer and prostatic diseases2026

Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.

Stephen J Freedland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.